Europe’s Medicines Question: One-Bloc Negotiation or Country-by-Country Bargaining?

The European Parliament has begun a critical debate over whether Brussels should consolidate its purchasing power for essential medicines or allow Member States to continue negotiating independently with major pharmaceutical suppliers, a decision that could reshape how 450 million Europeans access vital treatments.

Karin Karlsbro, the lead negotiator for the centrist Renew Europe group, opened the discussion on 21 May, framing the choice as one between leveraging the EU’s collective market strength and preserving national sovereignty over healthcare procurement. The debate comes as the Commission prepares to table its Critical Medicines Act in the third quarter of 2026, legislation expected to address long-standing vulnerabilities in Europe’s pharmaceutical supply chains.

The Case for Collective Bargaining

Proponents of bloc-wide negotiation argue that the EU’s substantial consumer base represents untapped leverage in dealings with pharmaceutical giants based in the United States and China. When Member States negotiate separately, they compete against one another for limited supplies, potentially driving up prices and creating shortages in smaller markets.

“The question before us is whether we use our collective strength of 450 million consumers or continue to bargain as twenty-seven separate markets,” Karlsbro said in opening the debate. “The answer will determine not just prices, but availability and security of supply for medicines Europeans depend upon.”

National Prerogatives and Healthcare Sovereignty

The debate has exposed familiar tensions between supranational coordination and national control over healthcare policy, an area where Member States have historically guarded their autonomy. Countries with established pharmaceutical industries and existing bilateral relationships with major suppliers may resist ceding negotiating authority to Brussels.

Healthcare remains a national competence under EU treaties, though the bloc has steadily expanded its role in areas such as cross-border patient rights and medicines authorisation. A shift to collective procurement for critical medicines would represent a significant evolution in EU health policy, requiring either new legislative mechanisms or voluntary coordination amongst capitals.

Lessons from Recent Crises

The COVID-19 pandemic exposed the fragility of pharmaceutical supply chains and the consequences of fragmented European procurement. Initial scrambles for protective equipment and vaccines saw Member States competing against one another, before the Commission ultimately coordinated a joint vaccination procurement strategy that demonstrated the potential benefits of unified action.

That experience has informed current discussions, with supporters of collective bargaining pointing to the improved negotiating position the EU achieved once it pooled demand. Critics, however, note that the vaccine procurement programme also faced criticism over speed and flexibility compared to more nimble national approaches.

Geopolitical Dimensions

The focus on US and Chinese pharmaceutical suppliers reflects broader European concerns about strategic dependencies on external powers for critical goods. Both countries host major pharmaceutical manufacturing capacity and research centres, making them essential partners for European medicine security.

A unified EU negotiating stance could theoretically strengthen Europe’s position vis-à-vis these suppliers, but would require unprecedented coordination on technical specifications, pricing thresholds, and distribution mechanisms across Member States with varying healthcare systems and budgetary constraints.

The Road to the Critical Medicines Act

The Commission’s forthcoming legislative proposal will need to navigate these competing priorities whilst addressing practical questions about which medicines qualify as critical, how collective procurement would operate alongside existing national systems, and what enforcement mechanisms might ensure compliance.

Parliament’s current debate serves as an early sounding board for these issues, allowing political groups to stake out positions before formal negotiations begin. Renew Europe’s decision to lead on this issue signals the centrist group’s ambition to shape health policy, traditionally an area where the centre-right European People’s Party and centre-left Socialists and Democrats have dominated.

As the third quarter of 2026 approaches, the pharmaceutical industry, Member State governments, and patient advocacy groups will be watching closely to see whether the Commission opts for mandatory collective procurement, a voluntary coordination framework, or something in between. The outcome will have implications not only for medicine prices and availability, but for the broader question of how far European integration can extend into areas of core national sensitivity. With global pharmaceutical supply chains under increasing strain and geopolitical competition intensifying, the pressure to find a unified European answer has never been greater.